Eli Lilly is selling to Amphastar Pharmaceuticals global rights to Baqsimi, an emergency treatment for severe hypoglycemia in diabetes patients. The deal come as Lilly turns its focus to novel medicines for diabetes and other indications.
Currently Amphastar Pharmaceuticals has dominated the market producing the drug naloxone which can reverse a heroin overdose. With more and more people struggling with heroin addiction in the country, is it fair that the company has practically doubled the price of the drug just this year?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.